Last reviewed · How we verify
Norepinephrine and Vasopressin for Rescue
This combination therapy uses norepinephrine and vasopressin to increase blood pressure and peripheral vascular resistance in patients with refractory hypotension or shock.
This combination therapy uses norepinephrine and vasopressin to increase blood pressure and peripheral vascular resistance in patients with refractory hypotension or shock. Used for Refractory hypotension or shock in critically ill patients, Septic shock unresponsive to standard vasopressor therapy.
At a glance
| Generic name | Norepinephrine and Vasopressin for Rescue |
|---|---|
| Sponsor | Hospital do Coracao |
| Drug class | Vasopressor combination |
| Target | Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, V1 vasopressin receptor |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Norepinephrine is a catecholamine that acts on alpha and beta adrenergic receptors to increase heart rate, contractility, and vasoconstriction. Vasopressin (antidiuretic hormone) acts on V1 receptors on vascular smooth muscle to cause vasoconstriction. Together, they are used as rescue vasopressors in critically ill patients with hypotension unresponsive to standard therapies.
Approved indications
- Refractory hypotension or shock in critically ill patients
- Septic shock unresponsive to standard vasopressor therapy
Common side effects
- Tachycardia
- Arrhythmias
- Peripheral vasoconstriction / tissue ischemia
- Hypertension
- Headache
Key clinical trials
- Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: